McAuley Andrew, Munro Alison, Bird Sheila M, Hutchinson Sharon J, Goldberg David J, Taylor Avril
Health Protection Scotland, Meridian Court, Cadogan Street, Glasgow G2 6QE, UK; Institute for Applied Health Research, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow G4 0BA, UK.
School of Media, Culture and Society, University of the West of Scotland, Paisley PA1 2BE, UK.
Drug Alcohol Depend. 2016 May 1;162:236-40. doi: 10.1016/j.drugalcdep.2016.02.031. Epub 2016 Mar 3.
Availability of the opioid antagonist naloxone for lay administration has grown substantially since first proposed in 1996. Gaps remain, though, in our understanding of how people who inject drugs (PWID) engage with naloxone programmes over time.
This paper aimed to address three specific evidence gaps: the extent of naloxone supply to PWID; supply-source (community or prisons); and the carriage of naloxone among PWID.
Analysis of Scotland's Needle Exchange Surveillance Initiative (NESI) responses in 2011-2012 and 2013-2014 was undertaken with a specific focus on the extent of Scotland's naloxone supply to PWID; including by source (community or prisons); and on the carriage of naloxone. Differences in responses between the two surveys were measured using Chi-square tests together with 95% confidence intervals for rate-differences over time.
The proportion of NESI participants who reported that they had been prescribed naloxone within the last year increased significantly from 8% (175/2146; 95% CI: 7-9%) in 2011-2012 to 32% (745/2331; 95% CI: 30% to 34%) in 2013-2014. In contrast, the proportion of NESI participants who carried naloxone with them on the day they were interviewed decreased significantly from 16% (27/169; 95% CI: 10% to 22%) in 2011-2012 to 5% (39/741; 95% CI: 4% to 7%) in 2013-2014.
The supply of naloxone to PWID has increased significantly since the introduction of a National Naloxone Programme in Scotland in January 2011. In contrast, naloxone carriage is low and decreased between the two NESI surveys; this area requires further investigation.
自1996年首次提出以来,可供非专业人员使用的阿片类拮抗剂纳洛酮的可及性有了显著提高。然而,我们对注射吸毒者(PWID)如何长期参与纳洛酮项目的了解仍存在差距。
本文旨在解决三个具体的证据空白:向注射吸毒者提供纳洛酮的程度;供应来源(社区或监狱);以及注射吸毒者随身携带纳洛酮的情况。
对苏格兰2011 - 2012年和2013 - 2014年针头交换监测倡议(NESI)的回复进行分析,特别关注苏格兰向注射吸毒者提供纳洛酮的程度,包括供应来源(社区或监狱)以及纳洛酮的携带情况。使用卡方检验以及随时间变化的率差的95%置信区间来衡量两次调查回复的差异。
报告在过去一年中被开具纳洛酮处方的NESI参与者比例从2011 - 2012年的8%(175/2146;95%置信区间:7 - 9%)显著增加到2013 - 2014年的32%(745/2331;95%置信区间:30%至34%)。相比之下,在接受访谈当天随身携带纳洛酮的NESI参与者比例从2011 - 2012年的16%(27/169;95%置信区间:10%至22%)显著下降到2013 - 2014年的5%(39/741;95%置信区间:4%至7%)。
自2011年1月苏格兰推出国家纳洛酮项目以来,向注射吸毒者提供纳洛酮的情况显著增加。相比之下,纳洛酮的携带率较低,且在两次NESI调查之间有所下降;这一领域需要进一步调查。